BLUE bluebird bio Inc.

72.96
-5.01  -6%
Previous Close 77.97
Open 77.75
Price To Book 2.74
Market Cap 4,036,949,760
Shares 55,331,000
Volume 1,584,114
Short Ratio
Av. Daily Volume 761,577
Stock charts supplied by TradingView

NewsSee all news

  1. bluebird bio to Present New Data from Gene and Cell Therapy Programs at 61st American Society of Hematology Annual Meeting and Exposition

    Updated safety and efficacy results from ongoing Phase 1 CRB-402 study of bb21217 in relapsed/refractory multiple myeloma Updated results from ongoing Phase 1/2 (HGB-206) study of LentiGlobin™ gene therapy for

  2. bluebird bio Reports Third Quarter 2019 Financial Results and Highlights Operational Progress

    - Continued progress towards 2022 vision of four marketed gene and cell therapy products with robust development pipeline - - ZYNTEGLO commercial launch advancing with European Medicines Agency approval of refined

  3. bluebird bio Announces Transition of Chief Strategy Officer Jeffrey T. Walsh

    bluebird bio, Inc. (NASDAQ:BLUE) today announced that Jeffrey T. Walsh, chief strategy officer, has decided to transition from his current role effective January 6, 2020. "On behalf of bluebird, we are grateful for

  4. European Medicines Agency Approves Refined Commercial Manufacturing Specifications for ZYNTEGLO™

    First gene therapy for patients 12 years and older with transfusion-dependent β-thalassemia who do not have a β0/β0 genotype now available to be manufactured in the European Union bluebird bio, Inc. (NASDAQ:BLUE)

  5. bluebird bio and Novo Nordisk Enter into Research Agreement to Develop in vivo Genome Editing Candidates for Haemophilia and Other Severe Genetic Diseases

    bluebird bio, Inc. (NASDAQ:BLUE) and Novo Nordisk A/S (NVO) today announced that they have entered into a research collaboration to jointly develop next-generation in vivo genome editing treatments for genetic diseases,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial to be initiated by end of 2019.
LentiGlobin - HGB-210
Sickle Cell Disease (SCD)
Phase 3 presentation of data at ASH December 9, 2019, 5:30 p.m ET.
LentiGlobin - HGB-212 Northstar-3
TDT and the β0/β0genotype
Phase 2 data due by the end of 2019.
bb2121 - KarMMa
Relapsed/refractory multiple myeloma
Phase 3 presentation of data at ASH December 9, 2019, 6pm.
LentiGlobin - HGB-207 Northstar-2
non-β0/β0 transfusion-dependent thalassemia (TDT)
Phase 2/3 updated data September 18, 2019 noted 88% (N=15/17) continue to be alive and MFD-free.
Lenti-D - Starbeam
Childhood cerebral adrenoleukodystrophy (CCALD)
Updated data due at EHA June 14, 2019 noted 3.8 years of transfusion independence in patients who do not have a β0/β0 genotype.
LentiGlobin - HGB-204
β-Thalassemia
Phase 1/2 presentation of data due at ASH December 7, 2019, 5:30pm.
LentiGlobin - HGB-206
Sickle disease
Phase 1 data due at ASH December 9, 2019, 6:45 p.m. ET.
bb21217
Multiple Myeloma

Latest News

  1. bluebird bio to Present New Data from Gene and Cell Therapy Programs at 61st American Society of Hematology Annual Meeting and Exposition

    Updated safety and efficacy results from ongoing Phase 1 CRB-402 study of bb21217 in relapsed/refractory multiple myeloma Updated results from ongoing Phase 1/2 (HGB-206) study of LentiGlobin™ gene therapy for

  2. bluebird bio Reports Third Quarter 2019 Financial Results and Highlights Operational Progress

    - Continued progress towards 2022 vision of four marketed gene and cell therapy products with robust development pipeline - - ZYNTEGLO commercial launch advancing with European Medicines Agency approval of refined

  3. bluebird bio Announces Transition of Chief Strategy Officer Jeffrey T. Walsh

    bluebird bio, Inc. (NASDAQ:BLUE) today announced that Jeffrey T. Walsh, chief strategy officer, has decided to transition from his current role effective January 6, 2020. "On behalf of bluebird, we are grateful for

  4. European Medicines Agency Approves Refined Commercial Manufacturing Specifications for ZYNTEGLO™

    First gene therapy for patients 12 years and older with transfusion-dependent β-thalassemia who do not have a β0/β0 genotype now available to be manufactured in the European Union bluebird bio, Inc. (NASDAQ:BLUE)

  5. bluebird bio and Novo Nordisk Enter into Research Agreement to Develop in vivo Genome Editing Candidates for Haemophilia and Other Severe Genetic Diseases

    bluebird bio, Inc. (NASDAQ:BLUE) and Novo Nordisk A/S (NVO) today announced that they have entered into a research collaboration to jointly develop next-generation in vivo genome editing treatments for genetic diseases,

  6. bluebird bio Appoints William R. Sellers, M.D. to Board of Directors

    bluebird bio, Inc. (NASDAQ:BLUE) today announced that it has appointed William R. Sellers, M.D. to its Board of Directors. "I'm excited to welcome Bill to the Board to help navigate an important stage in bluebird's

  7. bluebird bio Presents Updated Data from Phase 2/3 Clinical Study of Lenti-D™ Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the 13th European Pediatric Neurology Society (EPNS) Congress

    Long-Term Follow-up Data Show That the 88% of Patients Treated in the Starbeam Study (ALD-102) Were Free of Major Functional Disabilities (MFDs) at Two Years, and Continued to Remain MFD-Free at up to Five Years of

  8. bluebird bio to Present Data from Clinical Development Program of Lenti-DTM Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the 13th European Pediatric Neurology Society (EPNS) Congress

    Data Include Updates from Phase 2/3 Starbeam Study (ALD-102) of Lenti-D for CALD and Ongoing Observational Study (ALD-103) of Allogeneic Hematopoietic Stem Cell Transplant for CALD bluebird bio, Inc. (NASDAQ:BLUE)

  9. bluebird bio Announces Investor Events in September

    bluebird bio, Inc. (NASDAQ:BLUE) today announced that members of the management team will present at the following upcoming investor conferences in September: Citi 14th Annual Biotech Conference, Wednesday, September